


PATENT COOPERATION TREATY

OD:262

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

F B Rice & Co
605 Darling Street
BALMAIN NSW 2041

PCT

WRITTEN OPINION
(PCT Rule 66)Date of mailing
(day/month/year)

23 FEB 2004

Applicant's or agent's file reference

115565/BAL

REPLY DUE

within TWO MONTHS
from the above date of mailing

International Application No.

PCT/AU2003/001912

International Filing Date (day/month/year)

11 August 2003

Priority Date (day/month/year)

9 August 2002

International Patent Classification (IPC) or both national classification and IPC

Int. Cl. A61F 11/00, A61B 17/56

Applicant

COCHLEAR LIMITED et al.

- This written opinion is the **first** drawn by this International Preliminary Examining Authority.
- This opinion contains indications relating to the following items:
 - Basis of the opinion
 - Priority
 - Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - Lack of unity of invention
 - Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement
 - Certain documents cited
 - Certain defects in the international application
 - Certain observations on the international application
- The **FINAL DATE** by which the international preliminary examination report must be established according to Rule 69.2 is:
9 December 2004
- The applicant is hereby invited to reply to this opinion.

When? See the Reply Due date indicated above. However, the Australian Patent Office will not establish the Report before the earlier of (i) a response being filed, or (ii) one month before the Final Date by which the international preliminary examination report must be established. The Report will take into account any response (including amendments) filed before the Report is established. If no response is filed by 1 month before the Final Date, the international preliminary examination report will be established on the basis of this opinion.

Applicants wishing to have the benefit of a further opinion (if needed) before the report is established should ensure that a response is filed at least 3 months before the Final Date by which the international preliminary examination report must be established.

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3.
For the form and the language of the amendments, see Rules 66.5 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4(b).
For an informal consultation with the examiner, see Rule 66.6.

Name and mailing address of the IPEA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 266, WODEN ACT 2606, AUSTRALIA
E-mail address: pte@ipausa.gov.au
Facsimile No: (02) 6285 3929

Authorized Officer

SUE THOMAS

Telephone No. (02) 6283 2454

WRITTEN OPINION

International application No.
PCT/AU2003/001012

Basis of the opinion

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed."

WRITTEN OPINION

International application No.

PCT/AU2003/001012

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 16-19, 21, 26, 32-42	YES
	Claims 1-15, 20, 22-25, 27-31	NO
Inventive step (IS)	Claims 16-19, 21, 36-40, 42	YES
	Claims 1-15, 20, 22-35, 41	NO
Industrial applicability (IA)	Claims 1-42	YES
	Claims	NO

2. Citations and explanations

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1....US 6,427,086

D2....US 6,132,384

Novelty (N) Claims 1-15, 20, 22-25, 27-31

Claims 1-10, 12-15, 20, 22-25, 27-31: D1 discloses a neurostimulator (620) implantable into cavity in the cranium; the upper surface of the implant having a flange member (622) extending outwardly beyond the outward extent of the lower surface of the housing, the flange member adapted to abut the surface of the bone surrounding the cavity (column 35 lines 1 to 4).

Similarly D2 discloses the features of claims 1-5, 13, 14

Claim 11: D2 discloses a flange (158) which is an integral extension of the implant.

Inventive Step (IS) Claims 1-15, 20, 22-35, 41

Claims 1-15, 20, 22-25, 27-31 lack novelty and consequently lack inventive step.

Claims 26: Although D1 does not disclose the feature of making the flange integral with the faceplate, this would be considered obvious to a PSA and consequently lacks inventive step.

Claim 32-35: Although D1 does not disclose the feature of making the faceplate separately from the housing, this would be considered obvious to a PSA and consequently lacks inventive step.

Claim 41: Although D1 does not disclose all the steps of the method claimed, they would be considered obvious to a PSA and consequently lack inventive step.